Dabigatran etexilate [211915-06-9]

Catalog number: HY-10274_5mg
Brand: MedChem Express
Packing: 5 mg
Other sizes: 10 mM
10 mg
50 mg
100 mg
Price: € 103.50 € 115.00
Expected delivery time: 10 days

Product specifications for - Dabigatran etexilate [211915-06-9]

Product group: Chemicals
Category: Inhibitors / activators
CAS No.: 211915-06-9
Purity: >98%
Molecular Formula: C34H41N7O5
Molecular weight: 627.7332
Datasheet: Datasheet
  Research Use Only
UNSPSC: 12352200
Scientific information: 
Scientific info: Dabigatran etexilate(BIBR-1048) is the orally active prodrug of dabigatran, Dabigatran is a reversible and selective, direct thrombin inhibitor (DTI) with Ki value of 4.5 nM. IC50 Value: 4.5 nM (Ki), 10 nM(Thrombin-induced platelet aggregation) [1] in vitro: Dabigatran selectively and reversibly inhibited human thrombin(Ki: 4.5 nM) as well as thrombin-induced platelet aggregation (IC(50): 10 nM), while showing no inhibitory effect on other platelet-stimulating agents.Thrombin generation in platelet-poor plasma (PPP), measured as the endogenous thrombin potential (ETP) was inhibited concentration-dependently (IC(50): 0.56 microM). Dabigatran demonstrated concentration-dependent anticoagulant effects in various species in vitro, doubling the activated partial thromboplastin time (aPTT), prothrombin time (PT) and ecarin clotting time (ECT) in human PPP at concentrations of 0.23, 0.83 and 0.18 microM, respectively [1]. in vivo: Dabigatran prolonged the aPTT dose-dependently after intravenous administration in rats (0.3, 1 and 3 mg/kg) and rhesus monkeys (0.15, 0.3 and 0.6 mg/kg). Dose- and time-dependent anticoagulant effects were observed with dabigatran etexilate administered orally to conscious rats (10, 20 and 50 mg/kg) or rhesus monkeys (1, 2.5 or 5 mg/kg), with maximum effects observed between 30 and 120 min after administration, respectively [1]. Patients treated with dabigatran etexilate experienced fewer ischaemic strokes (3.74 dabigatran etexilate vs 3.97 warfarin) and fewer combined intracranial haemorrhages and haemorrhagic strokes (0.43 dabigatran etexilate vs 0.99 warfarin) per 100 patient-years [2]. Clinical trial: An Evaluation of the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate in Hemodialysis Patients . Phase1
Safety information: 
Additional information: 
Synonyms: HY-10274; BIBR 1048; BIBR-1048
Dabigatran Etexilate Activation is Affected by the CES1 Genetic Polymorphism G143E (rs71647871) andGender.', Shi J. Biochem Pharmacol. 2016 Nov 1;119:76-84. Read more